These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11556191)

  • 21. [IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
    Lehnert H; Bramlage P; Pittrow D; Kirch W
    MMW Fortschr Med; 2003 Oct; 145 Suppl 3():81-7. PubMed ID: 15490772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical overview of irbesartan: expanding the therapeutic window in hypertension.
    Man in't Veld AJ
    J Hypertens Suppl; 1997 Dec; 15(7):S27-33. PubMed ID: 9532518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
    Ceriello A; Motz E
    N Engl J Med; 2002 Feb; 346(9):705-7. PubMed ID: 11873779
    [No Abstract]   [Full Text] [Related]  

  • 24. Summaries for patients. Effects of blood pressure drugs in patients with diabetes and kidney disease.
    Ann Intern Med; 2003 Apr; 138(7):I43. PubMed ID: 12667050
    [No Abstract]   [Full Text] [Related]  

  • 25. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
    Palmer AJ; Valentine WJ; Ray JA
    Int J Clin Pract; 2007 Oct; 61(10):1626-33. PubMed ID: 17877649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. End-stage renal failure after irbesartan prescription in a diabetic patient with previously stable chronic renal insufficiency.
    Descombes E; Fellay G
    Ren Fail; 2000 Nov; 22(6):815-21. PubMed ID: 11104169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Microalbuminuria in patients with hypertension and cardiovascular comorbidity, REAL observational study of treatment with Irbesartan/HCTZ].
    Tschöpe C; Tschöpe R; Unger T
    MMW Fortschr Med; 2006 Jun; 148(25):48. PubMed ID: 16859162
    [No Abstract]   [Full Text] [Related]  

  • 28. Losartan for hypertension.
    Med Lett Drugs Ther; 1995 Jun; 37(951):57-8. PubMed ID: 7783693
    [No Abstract]   [Full Text] [Related]  

  • 29. Preventing nephropathy in patients with type 2 diabetes.
    Manag Care Interface; 2002 Jan; 15(1):72-5. PubMed ID: 11828609
    [No Abstract]   [Full Text] [Related]  

  • 30. What is the impact of PRIME on real-life diabetic nephropathy?
    Ruilope LM
    Int J Clin Pract; 2004 Mar; 58(3):268-76. PubMed ID: 15117095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension?
    Ruggenenti P; Remuzzi G
    Nat Clin Pract Nephrol; 2006 May; 2(5):250-1. PubMed ID: 16932436
    [No Abstract]   [Full Text] [Related]  

  • 33. Angiotensin receptor antagonists.
    Wong W; Howes L
    Aust Fam Physician; 2000 Jul; 29(7):653-5, 658. PubMed ID: 10914449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Irbesartan for hypertension.
    Med Lett Drugs Ther; 1998 Jan; 40(1019):18-9. PubMed ID: 9465857
    [No Abstract]   [Full Text] [Related]  

  • 35. [Angiotensin II receptor antagonists. Clinical relevance].
    Scholze J
    Internist (Berl); 1996 Jun; 37(6):636-42. PubMed ID: 8767999
    [No Abstract]   [Full Text] [Related]  

  • 36. [Health economic aspects of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
    Schute LL
    Dtsch Med Wochenschr; 2004 Jun; 129(25-26):1448; author reply 1448. PubMed ID: 15213879
    [No Abstract]   [Full Text] [Related]  

  • 37. Renoprotection in Type 2 diabetes: blockade of the renin-angiotensin system with angiotensin II receptor blockers.
    Swift PA; MacGregor GA
    J Renin Angiotensin Aldosterone Syst; 2001 Sep; 2(3):170-3. PubMed ID: 11881118
    [No Abstract]   [Full Text] [Related]  

  • 38. Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
    Studney D
    Can J Cardiol; 2002 May; 18 Suppl A():3A-6A. PubMed ID: 12045787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A threat to cardiovascular risk patients. "Activated renin-angiotensin system promotes end organ damage" (interview by Waldtraud Paukstadt)].
    Schunkert H
    MMW Fortschr Med; 2004 Jun; 146(23):60. PubMed ID: 15373137
    [No Abstract]   [Full Text] [Related]  

  • 40. Losartan and angina pectoris.
    Ahmad S
    Tex Heart Inst J; 1995; 22(4):347-8. PubMed ID: 8605440
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.